Dr. Russell K. Hales, MD

Dr. Hales practices at Johns Hopkins Bayview Medical Center in Baltimore, Maryland, part of Johns Hopkins Health System.

Dr. Hales' NPI, 1033255138, was assigned on January 29, 2007. Dr. Hales graduated from The Johns Hopkins University School of Medicine in 2005. Dr. Hales holds Maryland license D70510.

Dr. Hales' primary practice is Johns Hopkins Bayview Medical Center, at 4940 Eastern Avenue, Baltimore, MD 21224 in Baltimore City. The practice phone is (410) 550-0123.

Dr. Hales' primary practice is Johns Hopkins Bayview Medical Center in Baltimore, Maryland, part of Johns Hopkins Health System. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Hales to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hales practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Hales' primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Hales is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Hales' licenses on file in 4 states: Maryland, Virginia, District of Columbia and Pennsylvania.

Dmand AI lists bone cancer radiation, brain tumor radiation, cancer radiation-upper GI, head & neck cancer radiation, lung cancer radiation and prostate cancer radiation among the conditions Dr. Hales treats.

CMS data shows 5,565 Medicare services from Dr. Hales across 16 procedure codes in 2024, for 400 Medicare patients. Medicare paid $460,892 for them.

CMS counts 400 Medicare patients who saw Dr. Hales in 2024. The largest group is 65 to 74, with 183 patients. 75% of them have cancer, and 75% have high blood pressure. 16% are also on Medicaid. Their average risk score is 2.40, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hales' median patient age at 75, with 49% women.

In 2024, Dr. Hales wrote 54 Medicare Part D claims for 25 patients. 98% of them were for generic drugs. CMS names the drug for 22 of them, across 1 drug with 11 or more claims each, at $182 in total drug cost. In 2023, CMS named 33 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Hales for performance year 2024, reported as part of a group.

Dmand AI links 73 papers to Dr. Hales, published from 2003 to 2025. 2019 was the busiest year, with 10. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Brain Neoplasms. Dr. Hales has published most often in Clin Lung Cancer. Dr. Hales' most frequent co-authors are Khinh Ranh Voong, MD, Josephine Feliciano, MD and Patrick Forde, MD.

Dmand AI links Dr. Hales to 6 clinical trials, 2 of them phase 1/2 studies. 3 are still active or recruiting. Conditions studied include Small Cell Lung Carcinoma, Stomach Neoplasms and Carcinoma, Bronchogenic. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors the most, 6.

CMS Open Payments shows 5 general payments to Dr. Hales from 2 drug and device companies from 2022 to 2024. Consulting fees make up the largest share, 95% of the total. AstraZeneca Pharmaceuticals LP paid the most, $4,077.

Dmand AI lists 1 award for Dr. Hales, most recently CMS Stage 1 EHR in 2014.

Dr. Hales graduated from The Johns Hopkins University School of Medicine in 2005.

Dr. Hales is in network with 8 carriers, including Aetna, Blue Cross Blue Shield of Michigan and CareFirst BlueCross BlueShield. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.